AKT1 and neoplasm: Unfortunately, the immunosuppressant rapalogs (Temsirolimus, Everolimus) that target mTORC1 activation, showed a limited anti-cancer activity as they failed to inhibit mTORC2 activity and reactivated the tumor supportive Akt pathway (41, 67, 68).